Skip to main content
SpringerLink
Log in
Book cover

Precision in Pulmonary, Critical Care, and Sleep Medicine pp 71–85Cite as

Genetics of Idiopathic Pulmonary Fibrosis

  • Chapter
  • First Online:

Part of the book series: Respiratory Medicine ((RM))

Abstract

In the last two decades, there has been significant growth in our understanding of the genetics underlying idiopathic pulmonary fibrosis (IPF), a relentlessly progressive, incurable disease. Where once the pathogenesis of IPF remained a mystery, modern methods in genetics and genetic epidemiology have begun to point investigators toward a better understanding of why this disease occurs and also toward more personalized approaches to patient care via the identification of new potential therapeutic targets for IPF.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2017;6(2):138–53.

    Article  PubMed  Google Scholar 

  2. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.

    Article  PubMed  Google Scholar 

  3. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.

    Article  PubMed  Google Scholar 

  4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    Article  CAS  PubMed  Google Scholar 

  5. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    Article  CAS  PubMed  Google Scholar 

  6. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138–53.

    Article  PubMed  Google Scholar 

  7. Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, et al. Validation of multidisciplinary diagnosis in IPF. Lancet Respir Med. 2018;6(2):88–9.

    Article  PubMed  Google Scholar 

  8. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J. 2017;50(2):1700936.

    Article  PubMed  Google Scholar 

  9. Wells AU. Any fool can make a rule and any fool will mind it. BMC Med. 2016;14(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40.

    Article  PubMed  Google Scholar 

  11. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483–92.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS®trials. Respir Med. 2016;113:74–9.

    Article  PubMed  Google Scholar 

  13. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.

    Article  CAS  PubMed  Google Scholar 

  14. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.

    Article  CAS  PubMed  Google Scholar 

  15. Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017;9(8):2684–91.

    Article  PubMed  PubMed Central  Google Scholar 

  16. García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105(12):1902–7.

    Article  PubMed  Google Scholar 

  17. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002;57(4):338–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax. 2000;55(2):143–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lawson WE, Loyd JE. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc. 2006;3(4):345–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S47–50.

    CAS  PubMed  Google Scholar 

  21. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005;172(9):1146–52.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344(8):573–9.

    Article  CAS  PubMed  Google Scholar 

  23. Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med. 2015;191(4):417–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lee H-L, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest. 2005;127(6):2034–41.

    Article  PubMed  Google Scholar 

  25. Fernandez BA, Fox G, Bhatia R, Sala E, Noble B, Denic N, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res. 2012;13(1):64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59(11):977–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem. 2010;285(29):22103–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hamvas A, Nogee LM, White FV, Schuler P, Hackett BP, Huddleston CB, et al. Progressive lung disease and surfactant dysfunction with a deletion in surfactant protein C gene. Am J Respir Cell Mol Biol. 2004;30(6):771–6.

    Article  CAS  PubMed  Google Scholar 

  30. Nogee LM, Dunbar AE, Wert S, Askin F, Hamvas A, Whitsett JA. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest. 2002;121(3 Suppl):20S–1S.

    Article  PubMed  Google Scholar 

  31. Tredano M, Griese M, Brasch F, Schumacher S, de Blic J, Marque S, et al. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet A. 2004;126A(1):18–26.

    Article  PubMed  Google Scholar 

  32. Cameron HS, Somaschini M, Carrera P, Hamvas A, Whitsett JA, Wert SE, et al. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr. 2005;146(3):370–5.

    Article  CAS  PubMed  Google Scholar 

  33. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004;350(13):1296–303.

    Article  CAS  PubMed  Google Scholar 

  34. Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008;134(1):192–5.

    Article  CAS  PubMed  Google Scholar 

  35. Van Moorsel CHM, Van Oosterhout MFM, Barlo NP, De Jong PA, Van Der Vis JJ, Ruven HJT, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010;182(11):1419–25.

    Article  PubMed  CAS  Google Scholar 

  36. Beers MF, Mulugeta S. Surfactant protein C biosynthesis and its emerging role in conformational lung disease. Annu Rev Physiol. 2005;67:663–96.

    Article  CAS  PubMed  Google Scholar 

  37. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. 2002;347(26):2141–8.

    Article  PubMed  Google Scholar 

  38. Bridges JP, Wert SE, Nogee LM, Weaver TE. Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice. J Biol Chem. 2003;278(52):52739–46.

    Article  CAS  PubMed  Google Scholar 

  39. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol. 2005;32(6):521–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mulugeta S, Maguire JA, Newitt JL, Russo SJ, Kotorashvili A, Beers MF. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L720–9.

    Article  CAS  PubMed  Google Scholar 

  41. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012;13(10):693–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Vulliamy T, Dokal I. Dyskeratosis congenita. Semin Hematol. 2006;43(3):157–66.

    Article  CAS  PubMed  Google Scholar 

  43. Knight SW, Vulliamy TJ, Heiss NS, Matthijs G, Devriendt K, Connor JM, et al. 1.4 Mb candidate gene region for X linked dyskeratosis congenita defined by combined haplotype and X chromosome inactivation analysis. J Med Genet. 1998;35(12):993–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Armanios M, Chen J-L, Chang Y-PC, Brodsky RA, Hawkins A, Griffin CA, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102(44):15960–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita : their impact on telomere length and the diversity of clinical presentation. Blood. 2006;107(7):2680–5.

    Article  CAS  PubMed  Google Scholar 

  46. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5):447–9.

    Article  CAS  PubMed  Google Scholar 

  47. Armanios MY, Chen JJ-L, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356(13):1317–26.

    Article  CAS  PubMed  Google Scholar 

  48. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104(18):7552–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cronkhite J, Xing C, Raghu G. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(7):729–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Alder JK, Barkauskas CE, Limjunyawong N, Stanley SE, Kembou F, Tuder RM, et al. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci. 2015;112(16):201504780.

    Article  CAS  Google Scholar 

  51. Stuart BD, Choi J, Zaidi S, Xing C, Holohan B, Chen R, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet. 2015;47(5):512–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Cogan JD, Kropski JA, Zhao M, Mitchell DB, Rives L, Markin C, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med. 2015;191(6):646–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kannengiesser C, Borie R, Menard C, Reocreux M, Nitschke P, Gazal S, et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J. 2015;46(249816):474–85.

    Article  CAS  PubMed  Google Scholar 

  54. Alder JK, Stanley SE, Wagner CL, Hamilton M, Hanumanthu VS, Armanios M. Exome sequencing identifi es mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015;147(5):1361–8.

    Article  PubMed  Google Scholar 

  55. Stanley SE, Gable DL, Wagner CL, Carlile TM, Hanumanthu VS, Podlevsky JD, et al. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med. 2016;8(351):351ra107.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Kropski JA, Mitchell DB, Markin C, Polosukhin VV, Choi L, Johnson JE, et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest. 2014;146(1):e1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Borie R, Tabèze L, Thabut G, Nunes H, Cottin V, Marchand-Adam S, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J. 2016;48(6):1721–31.

    Article  CAS  PubMed  Google Scholar 

  58. Parry EM, Alder JK, Qi X, Chen JJ-L, Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008;45(10):654–6.

    Article  CAS  PubMed  Google Scholar 

  60. Seibold MA, Wise AAL, Speer MCM, Steel MP, Brown KKK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, et al. Muc5b is required for airway defence. Nature. 2014;505(7483):412–6.

    Article  CAS  PubMed  Google Scholar 

  62. Helling BA, Gerber AN, Kadiyala V, Sasse SK, Pedersen BS, Sparks L, et al. Regulation of MUC5B expression in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2017;57(1):91–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mathai SK, Schwartz DA, Warg LA. Genetic susceptibility and pulmonary fibrosis. Curr Opin Pulm Med. 2014;20(5):429.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013;68(5):436–41.

    Article  PubMed  Google Scholar 

  65. Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One. 2013;8(8):e70621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Wei R, Li C, Zhang M, Jones-Hall YL, Myers JL, Noth I, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. Transl Res. 2014;163(5):494–502.

    Article  CAS  PubMed  Google Scholar 

  68. Horimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology. 2015;20(3):439–44.

    Article  PubMed  Google Scholar 

  69. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest. 2015;147(2):460–4.

    Article  PubMed  Google Scholar 

  70. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 2017;5(11):869–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res. 2015;165(1):48–60.

    Article  CAS  PubMed  Google Scholar 

  72. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Juge P-A, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49(5):1602314.

    Article  PubMed  Google Scholar 

  75. Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, et al. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nat Commun. 2018;9(1):5363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, et al. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genet. 2016;17(1):74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2015;12(Suppl 2):S193–9.

    PubMed  PubMed Central  Google Scholar 

  79. Mathai SK, Yang IV, Schwarz MI, Schwartz DA. Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med. 2015;13(1):191.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Mathai SK, Schwartz DA. Taking the “I” out of IPF. Eur Respir J. 2015;45(6):1539.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014;2(7):557–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–101.

    Article  CAS  Google Scholar 

  86. Justet A, Thabut G, Manali E, Molina Molina M, Kannengiesser C, Cadranel J, et al. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J. 2018;51(3):1701875.

    Article  PubMed  CAS  Google Scholar 

  87. Borie R, Kannengiesser C, Hirschi S, Le Pavec J, Mal H, Bergot E, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant. 2015;34(4):538–46.

    Article  PubMed  Google Scholar 

  88. Tokman S, Singer JP, Devine MS, Westall GP, Aubert JD, Tamm M, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Hear Lung Transplant. 2015;34(10):1318–24.

    Article  Google Scholar 

  89. Silhan LL, Shah PD, Chambers DC, Snyder LD, Riise GC, Wagner CL, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J. 2014;44(1):178–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Newton CA, Kozlitina J, Lines JR, Kaza V, Torres F, Garcia CK. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post–lung transplantation survival. J Hear Lung Transplant. 2017;36(8):845–53.

    Article  Google Scholar 

  91. Mathai SK, Newton CA, Schwartz DA, Garcia CK. Pulmonary fibrosis in the era of stratified medicine. Thorax. 2016;71(12):1154.

    Article  PubMed  Google Scholar 

  92. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368(23):2192–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016;194:1514.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165(9):1322–8.

    Article  PubMed  Google Scholar 

  96. Ono S, Tanaka T, Ishida M, Kinoshita A, Fukuoka J, Takaki M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J. 2011;38(4):861–9.

    Article  CAS  PubMed  Google Scholar 

  97. Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, Alfano DN, et al. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest. 2013;144(3):794–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Campo I, Zorzetto M, Mariani F, Kadija Z, Morbini P, Dore R, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res. 2014;15:43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Epaud R, Delestrain C, Louha M, Simon S, Fanen P, Tazi A. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J. 2014;43(2):638–41.

    Article  PubMed  Google Scholar 

  100. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5(5):e10680.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364(16):1576–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, et al. Desmoplakin variants are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193(10):1151–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. Raphael Borie, Dr. Christopher J.G. Sigakis, Mr. Avram Walts, Dr. Yasushi Nakano, and Dr. Evgenia Dobrinskikh for their assistance in preparing figures for this manuscript.

Author information

Authors and Affiliations

  1. Interstitial Lung Disease Program, Center for Advanced Heart & Lung Disease, Baylor University Medical Center at Dallas, Dallas, TX, USA

    Susan K. Mathai

  2. Department of Internal Medicine, Texas A&M University College of Medicine, Dallas, TX, USA

    Susan K. Mathai

  3. Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA

    David A. Schwartz

Authors
  1. Susan K. Mathai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Schwartz .

Editor information

Editors and Affiliations

  1. Assistant Professor Pulmonary, Critical Care and Sleep Medicine Section, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

    Jose L. Gomez

  2. Assistant Professor of Informatics, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA

    Blanca E. Himes

  3. Boehringer-Ingelheim Endowed, Professor of Internal Medicine, Chief of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA

    Naftali Kaminski

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mathai, S.K., Schwartz, D.A. (2020). Genetics of Idiopathic Pulmonary Fibrosis. In: Gomez, J., Himes, B., Kaminski, N. (eds) Precision in Pulmonary, Critical Care, and Sleep Medicine. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-31507-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31507-8_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-31506-1

  • Online ISBN: 978-3-030-31507-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation